Loading...
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
BACKGROUND: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared with gemcitabine alone. METHODS: Nab-P is not dispensed i...
Saved in:
Published in: | BMC Cancer |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Artigo |
Language: | Inglês |
Published: |
BioMed Central
2016
|
Subjects: | |
Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5010686/ https://ncbi.nlm.nih.gov/pubmed/27590845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2671-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|